Literature DB >> 27807757

Heart Failure Secondary to Chagas Disease: an Emerging Problem in Non-endemic Areas.

Mahmoud Traina1,2, Sheba Meymandi1, Jason S Bradfield3,4.   

Abstract

Chagas disease affects millions of people worldwide. Though the majority of infected individuals remain asymptomatic, approximately 30 % of patients progress to develop cardiac manifestations and eventual heart failure. While vectorial transmission occurs predominantly in South America, Central America, and Mexico, millions of people originally from these endemic regions immigrate to non-endemic countries in North America, Europe, and Asia. Outside of rare specialized centers, health-care providers lack experience diagnosing and treating this disease. This lack of experience likely leads to far fewer Chagas disease patients being diagnosed than what actually exist in non-endemic countries, with subsequent adverse effect on patient outcomes and health-care expenses. Underdiagnosis increases the risk of developing cardiomyopathy, associated heart failure, and life-threatening ventricular arrhythmias as the disease progresses.

Entities:  

Keywords:  Asia; Chagas disease; Emerging; Europe; Heart failure; Non-endemic; United States

Mesh:

Year:  2016        PMID: 27807757     DOI: 10.1007/s11897-016-0305-9

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  59 in total

Review 1.  Sudden death in Chagas' disease.

Authors:  A Rassi; S G Rassi; A Rassi
Journal:  Arq Bras Cardiol       Date:  2001-01       Impact factor: 2.000

2.  [Prevalence of Trypanosoma cruzi infection and vertical transmission in Latin-American pregnant women in a health area of Biscay].

Authors:  Olatz Avila Arzanegui; Paloma Liendo Arenaza; Lorea Martinez Indart; Txanton Martinez Astorkiza; Maria Itziar Pocheville Guruceta; Maria Victoria Egurbide Arberas
Journal:  Enferm Infecc Microbiol Clin       Date:  2012-05-21       Impact factor: 1.731

3.  A new technique to perform epicardial mapping in the electrophysiology laboratory.

Authors:  E Sosa; M Scanavacca; A d'Avila; F Pilleggi
Journal:  J Cardiovasc Electrophysiol       Date:  1996-06

4.  Tolerance and safety of nifurtimox in patients with chronic chagas disease.

Authors:  Yves Jackson; Emilie Alirol; Laurent Getaz; Hans Wolff; Christophe Combescure; François Chappuis
Journal:  Clin Infect Dis       Date:  2010-10-08       Impact factor: 9.079

5.  Radiofrequency catheter ablation of ventricular tachycardia guided by nonsurgical epicardial mapping in chronic Chagasic heart disease.

Authors:  E Sosa; M Scanavacca; A D'Avila; G Bellotti; F Pilleggi
Journal:  Pacing Clin Electrophysiol       Date:  1999-01       Impact factor: 1.976

Review 6.  Chagas disease in Spain, the United States and other non-endemic countries.

Authors:  Joaquim Gascon; Caryn Bern; María-Jesús Pinazo
Journal:  Acta Trop       Date:  2009-07-29       Impact factor: 3.112

Review 7.  Epidemiology of Chagas disease in Europe: many calculations, little knowledge.

Authors:  Jörn Strasen; Tatjana Williams; Georg Ertl; Thomas Zoller; August Stich; Oliver Ritter
Journal:  Clin Res Cardiol       Date:  2013-08-29       Impact factor: 5.460

8.  Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.

Authors:  Israel Molina; Jordi Gómez i Prat; Fernando Salvador; Begoña Treviño; Elena Sulleiro; Núria Serre; Diana Pou; Sílvia Roure; Juan Cabezos; Lluís Valerio; Albert Blanco-Grau; Adrián Sánchez-Montalvá; Xavier Vidal; Albert Pahissa
Journal:  N Engl J Med       Date:  2014-05-15       Impact factor: 91.245

9.  Health policies to control Chagas disease transmission in European countries.

Authors:  Ana Requena-Méndez; Pere Albajar-Viñas; Andrea Angheben; Peter Chiodini; Joaquim Gascón; José Muñoz
Journal:  PLoS Negl Trop Dis       Date:  2014-10-30

10.  Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.

Authors:  Oliver Yun; M Angeles Lima; Tom Ellman; Wilma Chambi; Sandra Castillo; Laurence Flevaud; Paul Roddy; Fernando Parreño; Pedro Albajar Viñas; Pedro Pablo Palma
Journal:  PLoS Negl Trop Dis       Date:  2009-07-07
View more
  9 in total

1.  A New Development in Trypanosoma cruzi Detection.

Authors:  Herbert B Tanowitz; Louis M Weiss
Journal:  J Clin Microbiol       Date:  2017-01-11       Impact factor: 5.948

Review 2.  Chagas Disease in the United States: a Public Health Approach.

Authors:  Caryn Bern; Louisa A Messenger; Jeffrey D Whitman; James H Maguire
Journal:  Clin Microbiol Rev       Date:  2019-11-27       Impact factor: 26.132

3.  Cardiac inflammation and ventricular tachycardia in Chagas disease.

Authors:  Hilary Shapiro; Sheba Meymandi; Kalyanam Shivkumar; Jason S Bradfield
Journal:  HeartRhythm Case Rep       Date:  2017-06-20

4.  A novel nanoluciferase-based system to monitor Trypanosoma cruzi infection in mice by bioluminescence imaging.

Authors:  Erica Silberstein; Carylinda Serna; Stenio Perdigão Fragoso; Rana Nagarkatti; Alain Debrabant
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

5.  Experiences with Diagnosis and Treatment of Chagas Disease at a United States Teaching Hospital-Clinical Features of Patients with Positive Screening Serologic Testing.

Authors:  Peter Hyson; Lilian Vargas Barahona; Laura C Pedraza-Arévalo; Jonathan Schultz; Luisa Mestroni; Maria da Consolação Moreira; Matthew Taylor; Carlos Franco-Paredes; Esther Benamu; Poornima Ramanan; Anis Rassi; Kellie Hawkins; Andrés F Henao-Martínez
Journal:  Trop Med Infect Dis       Date:  2021-05-31

Review 6.  Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis.

Authors:  Lyda Z Rojas; Marija Glisic; Laura Pletsch-Borba; Luis E Echeverría; Wichor M Bramer; Arjola Bano; Najada Stringa; Asija Zaciragic; Bledar Kraja; Eralda Asllanaj; Rajiv Chowdhury; Carlos A Morillo; Oscar L Rueda-Ochoa; Oscar H Franco; Taulant Muka
Journal:  PLoS Negl Trop Dis       Date:  2018-06-13

Review 7.  Treatment of Chagas Disease in the United States.

Authors:  Sheba Meymandi; Salvador Hernandez; Sandy Park; Daniel R Sanchez; Colin Forsyth
Journal:  Curr Treat Options Infect Dis       Date:  2018-06-26

8.  Insights from quantitative and mathematical modelling on the proposed WHO 2030 goals for Chagas disease.

Authors: 
Journal:  Gates Open Res       Date:  2019-09-17

9.  Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies.

Authors:  Guilherme Wesley Peixoto da Fonseca; Tania Garfias Macedo; Nicole Ebner; Marcelo Rodrigues Dos Santos; Francis Ribeiro de Souza; Charles Mady; Liliam Takayama; Rosa Maria Rodrigues Pereira; Wolfram Doehner; Stefan D Anker; Carlos Eduardo Negrão; Maria Janieire de Nazaré Nunes Alves; Stephan von Haehling
Journal:  ESC Heart Fail       Date:  2020-08-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.